COPENHAGEN, Denmark, Sept. 05, 2017 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced upcoming posters and presentations related to its rare disease product candidates.
The eight oral and poster presentations will take place at the upcoming American Society for Bone and Mineral Research (ASBMR) annual meeting in Denver from September 8-11, 2017, and the 10th International Meeting of Pediatric Endocrinology (IMPE) in Washington, D.C. from September 14-17, 2017.
“This series of data presentations reflects the momentum we are gaining with our three rare disease endocrinology pipeline candidates and ongoing efforts to make a meaningful impact on patients’ lives,” said Jonathan Leff, M.D., Ascendis Pharma’s Chief Medical Officer. “This is a transformative period for Ascendis as we advance our pipeline to two clinical programs, TransCon Growth Hormone and TransCon PTH. We will soon have three unique product candidates in clinical development as TransCon CNP progresses into the clinic early next year.”
| ASBMR 2017: TransCon PTH |
|
| Title | Date/Time |
| Pharmacokinetics of TransCon PTH in Rat and Cynomolgus Monkey: a Sustained-Release PTH Prodrug for Treatment of Hypoparathyroidism
FR0252 (Plenary poster presentation) |
Friday, September 8
5:00 – 7:00 p.m. Mountain Time (MT) |
| TransCon PTH, a Sustained-Release PTH Prodrug for the Treatment of Hypoparathyroidism: Proof-of-Principle in Cynomolgus Monkeys and TPTx Rats
MO0682 (Poster session) |
Monday, September 11
12:00 – 2:00 p.m. MT |
| ASBMR 2017: TransCon CNP |
|
| Title | Date/Time |
| TransCon CNP, a Sustained-Release Prodrug of C-type Natriuretic Peptide, Exerts Positive Effects on Bone Growth in Juvenile Cynomolgus Monkeys and in a Mouse Model of Achondroplasia
FR0343 (Plenary poster presentation) |
Friday, September 8
5:00 – 7:00 p.m. MT |
| Pharmacokinetics and Cardiovascular Assessment of TransCon CNP, a Sustained-Release C-type Natriuretic Peptide Prodrug, for the Treatment of Achondroplasia
SU0337 (Poster session) |
Sunday, September 10
12:30 – 2:30 p.m. MT |
| TransCon CNP, a Sustained-Release Prodrug of C-type Natriuretic Peptide, Prevents Premature Synchondrosis Closure in an Achondroplasia Mouse Model
MO0707 (Poster session) |
Monday, September 11
12:00 – 2:00 p.m. MT |
| 10th International Meeting of Pediatric Endocrinology |
|
| Title | Date/Time |
| Development of a Long-Acting (LA) Growth Hormone (GH): Size Matters
1741 (Poster session) |
Thursday, September 14
5:45 – 6:45 p.m. Eastern Time (ET) |
| User Driven Development of a New Device for Weekly Growth Hormone Administration in Pediatric Patients
1458 (Poster session) |
Friday, September 15
11:30 a.m. – 12:30 p.m. ET |
| TransCon CNP, a Sustained-Release Prodrug of C-type Natriuretic Peptide, Exerts Positive Effects on Bone in Young Cynomolgus Monkeys and in a Mouse Model of Achondroplasia
1289 (Oral presentation FC57 during Free Communication session) |
Saturday, September 16
7:30 a.m. – 8:30 a.m. ET |
About Ascendis Pharma A/S
Ascendis Pharma is applying the TransCon technology platform to build a leading rare disease commercial company. The company utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases by improving clinically validated parent drugs and creating therapies with potential for best-in-class efficacy, safety and/or convenience.
Ascendis Pharma has a wholly-owned pipeline of rare disease endocrinology programs, including once-weekly TransCon Growth Hormone, which is currently being evaluated in the Phase 3 heiGHt Trial for children with growth hormone deficiency (GHD), TransCon PTH, a long-acting prodrug of parathyroid hormone for hypoparathyroidism, and TransCon CNP, a long-acting prodrug of C-type Natriuretic Peptide for achondroplasia. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology.
For more information, please visit www.ascendispharma.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our potential to become a leading, integrated rare disease company; (ii) our product pipeline; (iii) our ability to apply the TransCon technology platform to build a leading rare disease commercial company and (iv) our expectations regarding our ability to create therapies with potential for best-in-class efficacy, safety and/or convenience. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F for the year ended December 31, 2016, which we filed with the SEC on March 22, 2017. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.
CONTACT: Internal contact: Scott T. Smith Chief Financial Officer (650) 352-8389 ir@ascendispharma.com Investor contact: Patti Bank Westwicke Partners (415) 513-1284 patti.bank@westwicke.com Media contact: Ami Knoefler SparkBioComm (650) 739-9952 ami@sparkbiocomm.com
